mitoxantrone has been researched along with Bone Cancer in 45 studies
Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim was to determine the recommended dose of combined chemotherapy with mitoxantrone and uracil/tegafur (Phase I part) and to clarify its efficacy and safety in patients with advanced hepatocellular carcinoma at the recommended dose (Phase II part)." | 9.15 | A phase I/II study of combined chemotherapy with mitoxantrone and uracil/tegafur for advanced hepatocellular carcinoma. ( Furuse, J; Ikeda, M; Ishii, H; Mitsunaga, S; Morizane, C; Nakachi, K; Okusaka, T; Suzuki, E; Ueno, H, 2011) |
| "Palliation of bone pain can be achieved in men with androgen-independent prostate cancer treated with docetaxel and estramustine (DE) or mitoxantrone and prednisone (MP)." | 9.12 | Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone. ( Ankerst, DP; Berry, DL; Burch, PA; Crawford, ED; Hussain, MH; Jiang, CS; Jones, S; Lara, PN; Moinpour, CM; Petrylak, DP; Taplin, ME; Vinson, LV, 2006) |
| "Vinorelbine and mitoxantrone have both been demonstrated to have significant antitumor activity in patients with breast cancer." | 9.12 | Mitoxantrone plus vinorelbine in pretreated patients with metastatic breast cancer. ( Aravantinos, G; Bafaloukos, D; Fountzilas, G; Gogas, H; Kalofonos, HP; Koutras, A; Makatsoris, T; Mantzourani, M; Markopoulos, C; Onyenadum, A; Tzorakoelefterakis, E; Xiros, N, 2007) |
| "A total of 260 women with measurable metastatic breast cancer fulfilling high-risk criteria, previously untreated with chemotherapy for their metastatic disease, were randomized to receive either mitoxantrone 12 mg/m(2) or the combination of fluorouracil 500 mg/m(2), epirubicin 50 mg/m(2) and cyclophosphamide 500 mg/m(2) (FEC) every 3 weeks." | 9.10 | Is first-line single-agent mitoxantrone in the treatment of high-risk metastatic breast cancer patients as effective as combination chemotherapy? No difference in survival but higher quality of life were found in a multicenter randomized trial. ( Andreesen, R; Bodenstein, H; Clemens, M; Fehnle, K; Fischer, JT; Heidemann, E; Hirschmann, WD; Kaufmann, M; König, M; Mahlke, M; Oberhoff, C; Scharl, A; Schulze, M; Souchon, R; Stoeger, H, 2002) |
| "The purpose of this study was to determine the maximum-tolerated dose of gemcitabine plus mitoxantrone in women with metastatic breast cancer (MBC) and to evaluate activity and toxicity of this combination in a phase II trial." | 9.10 | Phase I/II study of gemcitabine plus mitoxantrone as salvage chemotherapy in metastatic breast cancer. ( Calabrese, P; Caporusso, L; Catino, A; Crucitta, E; D'Amico, C; De Lena, M; Guida, M; Latorre, A; Lorusso, V; Mazzei, A; Sambiasi, D; Schittulli, F; Silvestris, N, 2003) |
| "Men with HRPC, bone metastases, and bone pain were randomly assigned to receive clodronate 1,500 mg administered intravenously (IV) or placebo every 3 weeks, in combination with mitoxantrone 12 mg/m2 IV every 3 weeks and prednisone 5 mg orally bid." | 9.10 | Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain. ( Chi, K; Ding, K; Elliott, C; Ernst, DS; Moore, MJ; Parulekar, W; Reyno, L; Tannock, IF; Venner, PM; Winquist, EW, 2003) |
| "The purpose of this study was to compare the activity and toxicity of epirubicin-vindesine (EV) with mitoxantrone-vindesine (MV) in patients with metastatic breast cancer." | 9.08 | Randomised phase II study of epirubicin-vindesine versus mitoxantrone-vindesine in metastatic breast cancer. ( Fridrik, M; Hausmaninger, H; Hehenwarter, W; Lehnert, M; Manfreda, D; Samonigg, H; Schiller, L; Sevelda, P; Steger, G; Tschurtschenthaler, G, 1995) |
| "60 patients with metastatic breast cancer were entered in a phase II study using folinic acid, 5-fluorouracil bolus and infusion and mitoxantrone with or without cyclophosphamide." | 9.07 | Folinic acid, 5-fluorouracil bolus and infusion and mitoxantrone with or without cyclophosphamide in metastatic breast cancer. ( Beerblock, K; de Gramont, A; Demuynck, B; Guillot, T; Krulik, M; Louvet, C; Marpeau, L; Pigné, A; Soubrane, D; Varette, C, 1993) |
| "Two hundred and twenty-four patients with advanced breast cancer were enrolled in a multicenter prospective randomized clinical study and received either doxorubicin (40 mg/m2), or epirubicin (40 mg/m2) or mitoxantrone (12 mg/m2) each combined with cyclophosphamide (600 mg/m2) i." | 9.06 | Randomized clinical trial comparing mitoxantrone with epirubicin and with doxorubicin, each combined with cyclophosphamide in the first-line treatment of patients with metastatic breast cancer. ( Hartlapp, J; Heidemann, E; Hossfeld, D; Kunz, S; Neeser, E; Possinger, K; Schumacher, K; Steinke, B; von Ingersleben, G; Waldmann, R, 1990) |
| "Two cases of recurrent breast cancer are reported in which chemotherapy with mitoxantrone proved remarkably effective." | 7.70 | [Chemotherapy with mitoxantrone for the treatment of recurrent breast cancer]. ( Katagata, N; Matsuoka, T; Nomizu, T; Takenoshita, S; Tsuchiya, A; Watanabe, F; Yabuta, T; Yamaki, Y, 2000) |
| "A 67-year-old advanced breast cancer patient with multiple bone metastases showed a remarkable response to the combination therapy of mitoxantrone (MIT) and medroxyprogesteron acetate (MPA) after failure of anthracycline therapy." | 7.69 | [Advanced breast cancer with remarkable response to the combination therapy of mitoxantrone (MIT) and medroxyprogesteron acetate (MPA) after failure of anthracycline therapy: a case report]. ( Andoh, T; Iijima, T; Iino, Y; Inoue, T; Izumi, M; Kobayashi, I; Morishita, Y; Yamada, T; Yokoe, T; Yokota, T, 1994) |
| "Metastatic breast cancer remains an incurable disease and the median overall survival has not significantly improved over the past two decades." | 6.69 | Is salvage chemotherapy for metastatic breast cancer always effective and well tolerated? A phase II randomized trial of vinorelbine versus 5-fluorouracil plus leucovorin versus combination of mitoxantrone, 5-fluorouracil plus leucovorin. ( Comandini, D; Fusco, V; Merlini, L; Naso, C; Palumbo, R; Porcile, G; Pronzato, P; Repetto, L; Rosso, R; Simoni, C; Venturino, A, 2000) |
| "For previously treated advanced breast cancer, there is no standard second-line therapy." | 5.30 | Treatment of previously treated metastatic breast cancer by mitoxantrone and 48-hour continuous infusion of high-dose 5-FU and leucovorin (MFL): low palliative benefit and high treatment-related toxicity. ( Chen, PM; Chiou, TJ; Hsieh, RK; Liu, JH; Tung, SL; Wang, WS; Yen, CC, 1997) |
| "The aim was to determine the recommended dose of combined chemotherapy with mitoxantrone and uracil/tegafur (Phase I part) and to clarify its efficacy and safety in patients with advanced hepatocellular carcinoma at the recommended dose (Phase II part)." | 5.15 | A phase I/II study of combined chemotherapy with mitoxantrone and uracil/tegafur for advanced hepatocellular carcinoma. ( Furuse, J; Ikeda, M; Ishii, H; Mitsunaga, S; Morizane, C; Nakachi, K; Okusaka, T; Suzuki, E; Ueno, H, 2011) |
| "Palliation of bone pain can be achieved in men with androgen-independent prostate cancer treated with docetaxel and estramustine (DE) or mitoxantrone and prednisone (MP)." | 5.12 | Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone. ( Ankerst, DP; Berry, DL; Burch, PA; Crawford, ED; Hussain, MH; Jiang, CS; Jones, S; Lara, PN; Moinpour, CM; Petrylak, DP; Taplin, ME; Vinson, LV, 2006) |
| "Vinorelbine and mitoxantrone have both been demonstrated to have significant antitumor activity in patients with breast cancer." | 5.12 | Mitoxantrone plus vinorelbine in pretreated patients with metastatic breast cancer. ( Aravantinos, G; Bafaloukos, D; Fountzilas, G; Gogas, H; Kalofonos, HP; Koutras, A; Makatsoris, T; Mantzourani, M; Markopoulos, C; Onyenadum, A; Tzorakoelefterakis, E; Xiros, N, 2007) |
| "A total of 260 women with measurable metastatic breast cancer fulfilling high-risk criteria, previously untreated with chemotherapy for their metastatic disease, were randomized to receive either mitoxantrone 12 mg/m(2) or the combination of fluorouracil 500 mg/m(2), epirubicin 50 mg/m(2) and cyclophosphamide 500 mg/m(2) (FEC) every 3 weeks." | 5.10 | Is first-line single-agent mitoxantrone in the treatment of high-risk metastatic breast cancer patients as effective as combination chemotherapy? No difference in survival but higher quality of life were found in a multicenter randomized trial. ( Andreesen, R; Bodenstein, H; Clemens, M; Fehnle, K; Fischer, JT; Heidemann, E; Hirschmann, WD; Kaufmann, M; König, M; Mahlke, M; Oberhoff, C; Scharl, A; Schulze, M; Souchon, R; Stoeger, H, 2002) |
| "The purpose of this study was to determine the maximum-tolerated dose of gemcitabine plus mitoxantrone in women with metastatic breast cancer (MBC) and to evaluate activity and toxicity of this combination in a phase II trial." | 5.10 | Phase I/II study of gemcitabine plus mitoxantrone as salvage chemotherapy in metastatic breast cancer. ( Calabrese, P; Caporusso, L; Catino, A; Crucitta, E; D'Amico, C; De Lena, M; Guida, M; Latorre, A; Lorusso, V; Mazzei, A; Sambiasi, D; Schittulli, F; Silvestris, N, 2003) |
| "Men with HRPC, bone metastases, and bone pain were randomly assigned to receive clodronate 1,500 mg administered intravenously (IV) or placebo every 3 weeks, in combination with mitoxantrone 12 mg/m2 IV every 3 weeks and prednisone 5 mg orally bid." | 5.10 | Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain. ( Chi, K; Ding, K; Elliott, C; Ernst, DS; Moore, MJ; Parulekar, W; Reyno, L; Tannock, IF; Venner, PM; Winquist, EW, 2003) |
| "The purpose of this study was to compare the activity and toxicity of epirubicin-vindesine (EV) with mitoxantrone-vindesine (MV) in patients with metastatic breast cancer." | 5.08 | Randomised phase II study of epirubicin-vindesine versus mitoxantrone-vindesine in metastatic breast cancer. ( Fridrik, M; Hausmaninger, H; Hehenwarter, W; Lehnert, M; Manfreda, D; Samonigg, H; Schiller, L; Sevelda, P; Steger, G; Tschurtschenthaler, G, 1995) |
| "60 patients with metastatic breast cancer were entered in a phase II study using folinic acid, 5-fluorouracil bolus and infusion and mitoxantrone with or without cyclophosphamide." | 5.07 | Folinic acid, 5-fluorouracil bolus and infusion and mitoxantrone with or without cyclophosphamide in metastatic breast cancer. ( Beerblock, K; de Gramont, A; Demuynck, B; Guillot, T; Krulik, M; Louvet, C; Marpeau, L; Pigné, A; Soubrane, D; Varette, C, 1993) |
| "Two hundred and twenty-four patients with advanced breast cancer were enrolled in a multicenter prospective randomized clinical study and received either doxorubicin (40 mg/m2), or epirubicin (40 mg/m2) or mitoxantrone (12 mg/m2) each combined with cyclophosphamide (600 mg/m2) i." | 5.06 | Randomized clinical trial comparing mitoxantrone with epirubicin and with doxorubicin, each combined with cyclophosphamide in the first-line treatment of patients with metastatic breast cancer. ( Hartlapp, J; Heidemann, E; Hossfeld, D; Kunz, S; Neeser, E; Possinger, K; Schumacher, K; Steinke, B; von Ingersleben, G; Waldmann, R, 1990) |
| " The evaluated palliative treatments were pain medication only, chemotherapy consisting of mitoxantrone and prednisone, and single- and multifraction radiotherapy (RT)." | 3.72 | Radiotherapy is a cost-effective palliative treatment for patients with bone metastasis from prostate cancer. ( Konski, A, 2004) |
| "Two cases of recurrent breast cancer are reported in which chemotherapy with mitoxantrone proved remarkably effective." | 3.70 | [Chemotherapy with mitoxantrone for the treatment of recurrent breast cancer]. ( Katagata, N; Matsuoka, T; Nomizu, T; Takenoshita, S; Tsuchiya, A; Watanabe, F; Yabuta, T; Yamaki, Y, 2000) |
| "A 67-year-old advanced breast cancer patient with multiple bone metastases showed a remarkable response to the combination therapy of mitoxantrone (MIT) and medroxyprogesteron acetate (MPA) after failure of anthracycline therapy." | 3.69 | [Advanced breast cancer with remarkable response to the combination therapy of mitoxantrone (MIT) and medroxyprogesteron acetate (MPA) after failure of anthracycline therapy: a case report]. ( Andoh, T; Iijima, T; Iino, Y; Inoue, T; Izumi, M; Kobayashi, I; Morishita, Y; Yamada, T; Yokoe, T; Yokota, T, 1994) |
| "Cabozantinib treatment did not demonstrate better pain palliation than mitoxantrone-prednisone in heavily pretreated patients with mCRPC and symptomatic bone metastases." | 2.90 | Cabozantinib Versus Mitoxantrone-prednisone in Symptomatic Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 3 Trial with a Primary Pain Endpoint. ( Antonarakis, ES; Basch, EM; Bennett, AV; Chi, KN; Dayan, E; de Bono, JS; de Souza, P; Dreicer, R; Dueck, AC; George, S; Holland, J; Hutson, TE; Kalebasty, AR; Mangeshkar, M; Marx, G; O'Sullivan, JM; Scher, HI; Scholz, M; Schwarz, JK; Vaishampayan, U; Vogelzang, N; Weitzman, AL, 2019) |
| "Treatment with mitoxantrone plus prednisone was associated with greater and longer-lasting improvement in several HQL domains and symptoms than treatment with prednisone alone." | 2.69 | Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone. ( Ernst, DS; Neville, AJ; Osoba, D; Tannock, IF, 1999) |
| "Metastatic breast cancer remains an incurable disease and the median overall survival has not significantly improved over the past two decades." | 2.69 | Is salvage chemotherapy for metastatic breast cancer always effective and well tolerated? A phase II randomized trial of vinorelbine versus 5-fluorouracil plus leucovorin versus combination of mitoxantrone, 5-fluorouracil plus leucovorin. ( Comandini, D; Fusco, V; Merlini, L; Naso, C; Palumbo, R; Porcile, G; Pronzato, P; Repetto, L; Rosso, R; Simoni, C; Venturino, A, 2000) |
| "The burden of prostate cancer is inversely related to the magnitude of HRQOL declines." | 2.48 | Quality of life with advanced metastatic prostate cancer. ( Penson, DF; Resnick, MJ, 2012) |
| "Treatment of hormone-refractory prostate cancer is palliative, and surgery and radiotherapy are used for the relief of lower urinary tract symptoms and localized painful bony metastases." | 2.43 | The changing pattern of management for hormone-refractory, metastatic prostate cancer. ( Bloomfield, D; James, ND; Luscombe, C, 2006) |
| "For previously treated advanced breast cancer, there is no standard second-line therapy." | 1.30 | Treatment of previously treated metastatic breast cancer by mitoxantrone and 48-hour continuous infusion of high-dose 5-FU and leucovorin (MFL): low palliative benefit and high treatment-related toxicity. ( Chen, PM; Chiou, TJ; Hsieh, RK; Liu, JH; Tung, SL; Wang, WS; Yen, CC, 1997) |
| " Distribution and half-life data provide a pharmacological rationale for the use of mitoxantrone on an intermittent dosing schedule." | 1.27 | Pharmacology of mitoxantrone: mode of action and pharmacokinetics. ( Alberts, DS; Bowden, GT; Dalton, WS; Mackel, C; Peng, YM, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (8.89) | 18.7374 |
| 1990's | 14 (31.11) | 18.2507 |
| 2000's | 18 (40.00) | 29.6817 |
| 2010's | 9 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Thomas, C | 1 |
| Brandt, MP | 1 |
| Baldauf, S | 1 |
| Tsaur, I | 1 |
| Frees, S | 1 |
| Borgmann, H | 1 |
| Jäger, W | 1 |
| Bartsch, G | 1 |
| Schneider, M | 1 |
| Dotzauer, R | 1 |
| Neisius, A | 1 |
| Haferkamp, A | 1 |
| Basch, EM | 1 |
| Scholz, M | 1 |
| de Bono, JS | 1 |
| Vogelzang, N | 1 |
| de Souza, P | 1 |
| Marx, G | 1 |
| Vaishampayan, U | 1 |
| George, S | 1 |
| Schwarz, JK | 1 |
| Antonarakis, ES | 1 |
| O'Sullivan, JM | 1 |
| Kalebasty, AR | 1 |
| Chi, KN | 1 |
| Dreicer, R | 1 |
| Hutson, TE | 1 |
| Dueck, AC | 1 |
| Bennett, AV | 1 |
| Dayan, E | 1 |
| Mangeshkar, M | 1 |
| Holland, J | 1 |
| Weitzman, AL | 1 |
| Scher, HI | 1 |
| van Soest, RJ | 1 |
| de Morrée, ES | 1 |
| Shen, L | 1 |
| Tannock, IF | 5 |
| Eisenberger, MA | 2 |
| de Wit, R | 3 |
| Workenhe, ST | 1 |
| Pol, JG | 1 |
| Lichty, BD | 1 |
| Cummings, DT | 1 |
| Mossman, KL | 1 |
| Vignani, F | 1 |
| Bertaglia, V | 1 |
| Buttigliero, C | 1 |
| Tucci, M | 1 |
| Scagliotti, GV | 1 |
| Di Maio, M | 1 |
| Oudard, S | 1 |
| Banu, E | 1 |
| Medioni, J | 1 |
| Scotte, F | 1 |
| Banu, A | 1 |
| Levy, E | 1 |
| Wasserman, J | 1 |
| Kacso, G | 1 |
| Andrieu, JM | 1 |
| Olbert, PJ | 1 |
| Weil, C | 1 |
| Hegele, A | 1 |
| Hofmann, R | 1 |
| Schrader, AJ | 1 |
| Gopinath, SC | 1 |
| Wadhwa, R | 1 |
| Kumar, PK | 1 |
| Sonpavde, G | 1 |
| Pond, GR | 1 |
| Berry, WR | 1 |
| Armstrong, AJ | 2 |
| Suzuki, E | 1 |
| Furuse, J | 1 |
| Ikeda, M | 1 |
| Ishii, H | 1 |
| Okusaka, T | 1 |
| Nakachi, K | 1 |
| Mitsunaga, S | 1 |
| Ueno, H | 1 |
| Morizane, C | 1 |
| Resnick, MJ | 1 |
| Penson, DF | 1 |
| Heidemann, E | 2 |
| Stoeger, H | 1 |
| Souchon, R | 1 |
| Hirschmann, WD | 1 |
| Bodenstein, H | 1 |
| Oberhoff, C | 1 |
| Fischer, JT | 1 |
| Schulze, M | 1 |
| Clemens, M | 1 |
| Andreesen, R | 1 |
| Mahlke, M | 1 |
| König, M | 1 |
| Scharl, A | 1 |
| Fehnle, K | 1 |
| Kaufmann, M | 1 |
| Lorusso, V | 1 |
| Crucitta, E | 1 |
| Silvestris, N | 1 |
| Catino, A | 1 |
| Caporusso, L | 1 |
| Mazzei, A | 1 |
| Guida, M | 1 |
| Latorre, A | 1 |
| Sambiasi, D | 1 |
| D'Amico, C | 1 |
| Schittulli, F | 1 |
| Calabrese, P | 1 |
| De Lena, M | 1 |
| Ernst, DS | 2 |
| Winquist, EW | 1 |
| Venner, PM | 1 |
| Reyno, L | 1 |
| Moore, MJ | 1 |
| Chi, K | 1 |
| Ding, K | 1 |
| Elliott, C | 1 |
| Parulekar, W | 1 |
| Rexer, H | 1 |
| Konski, A | 1 |
| Dillman, RO | 1 |
| Barth, NM | 1 |
| VanderMolen, LA | 1 |
| Allen, K | 1 |
| Beutel, LD | 1 |
| Chico, S | 1 |
| Berry, DL | 1 |
| Moinpour, CM | 1 |
| Jiang, CS | 1 |
| Ankerst, DP | 1 |
| Petrylak, DP | 1 |
| Vinson, LV | 1 |
| Lara, PN | 1 |
| Jones, S | 1 |
| Taplin, ME | 1 |
| Burch, PA | 1 |
| Hussain, MH | 1 |
| Crawford, ED | 1 |
| James, ND | 1 |
| Bloomfield, D | 1 |
| Luscombe, C | 1 |
| Garrett-Mayer, E | 1 |
| Ou Yang, YC | 1 |
| Carducci, MA | 1 |
| Tannock, I | 1 |
| Eisenberger, M | 1 |
| Onyenadum, A | 1 |
| Gogas, H | 1 |
| Markopoulos, C | 1 |
| Bafaloukos, D | 1 |
| Aravantinos, G | 1 |
| Mantzourani, M | 1 |
| Koutras, A | 1 |
| Tzorakoelefterakis, E | 1 |
| Xiros, N | 1 |
| Makatsoris, T | 1 |
| Fountzilas, G | 1 |
| Kalofonos, HP | 1 |
| Thuret, R | 1 |
| Massard, C | 1 |
| Gross-Goupil, M | 1 |
| Escudier, B | 1 |
| Di Palma, M | 1 |
| Bossi, A | 1 |
| de Crevoisier, R | 1 |
| Chauchereau, A | 1 |
| Fizazi, K | 1 |
| Presant, CA | 1 |
| Gams, R | 1 |
| Bartolucci, AA | 1 |
| Kantoff, PW | 1 |
| Bezwoda, WR | 1 |
| Seymour, L | 1 |
| Dansey, RD | 1 |
| Grönemeyer, DH | 1 |
| Seibel, RM | 1 |
| Louvet, C | 1 |
| de Gramont, A | 1 |
| Demuynck, B | 1 |
| Beerblock, K | 1 |
| Varette, C | 1 |
| Soubrane, D | 1 |
| Marpeau, L | 1 |
| Pigné, A | 1 |
| Guillot, T | 1 |
| Krulik, M | 1 |
| Izumi, M | 1 |
| Iino, Y | 2 |
| Yokoe, T | 2 |
| Inoue, T | 1 |
| Yamada, T | 1 |
| Kobayashi, I | 1 |
| Andoh, T | 1 |
| Yokota, T | 1 |
| Iijima, T | 1 |
| Morishita, Y | 2 |
| Aoyagi, H | 1 |
| Maemura, M | 1 |
| Sugamata, N | 1 |
| Takai, Y | 1 |
| Horiguchi, J | 1 |
| Ishida, T | 1 |
| Ogilvie, GK | 1 |
| Straw, RC | 1 |
| Jameson, VJ | 1 |
| Walters, LM | 1 |
| Lafferty, MH | 1 |
| Powers, BE | 1 |
| Withrow, SJ | 1 |
| Hausmaninger, H | 1 |
| Lehnert, M | 1 |
| Steger, G | 1 |
| Sevelda, P | 1 |
| Tschurtschenthaler, G | 1 |
| Hehenwarter, W | 1 |
| Fridrik, M | 1 |
| Samonigg, H | 1 |
| Schiller, L | 1 |
| Manfreda, D | 1 |
| Stewart, DJ | 1 |
| Dahrouge, S | 1 |
| Yen, CC | 1 |
| Tung, SL | 1 |
| Hsieh, RK | 1 |
| Chiou, TJ | 1 |
| Liu, JH | 1 |
| Wang, WS | 1 |
| Chen, PM | 1 |
| Sauter, C | 1 |
| Stockler, MR | 1 |
| Osoba, D | 2 |
| Corey, P | 1 |
| Goodwin, PJ | 1 |
| Neville, AJ | 1 |
| Bashey, A | 1 |
| Corringham, S | 1 |
| Garrett, J | 1 |
| Lane, TA | 1 |
| Gilpin, EA | 1 |
| Corringham, RE | 1 |
| Law, P | 1 |
| Ho, AD | 1 |
| Matsuoka, T | 1 |
| Nomizu, T | 1 |
| Yabuta, T | 1 |
| Katagata, N | 1 |
| Watanabe, F | 1 |
| Yamaki, Y | 1 |
| Tsuchiya, A | 1 |
| Takenoshita, S | 1 |
| Venturino, A | 1 |
| Comandini, D | 1 |
| Simoni, C | 1 |
| Merlini, L | 1 |
| Naso, C | 1 |
| Palumbo, R | 1 |
| Fusco, V | 1 |
| Porcile, G | 1 |
| Pronzato, P | 1 |
| Rosso, R | 1 |
| Repetto, L | 1 |
| Carlson, LE | 1 |
| Koski, T | 1 |
| Glück, S | 1 |
| Auerbach, M | 1 |
| Elias, EG | 1 |
| Orford, J | 1 |
| Steinke, B | 1 |
| Hartlapp, J | 1 |
| Schumacher, K | 1 |
| Possinger, K | 1 |
| Kunz, S | 1 |
| Neeser, E | 1 |
| von Ingersleben, G | 1 |
| Hossfeld, D | 1 |
| Waldmann, R | 1 |
| Büyükünal, E | 1 |
| Derman, U | 1 |
| Serdengecti, S | 1 |
| Berkarda, B | 1 |
| Bull, FE | 1 |
| Von Hoff, DD | 1 |
| Balcerzak, SP | 1 |
| Stephens, RL | 1 |
| Panettiere, FJ | 1 |
| Alberts, DS | 1 |
| Peng, YM | 1 |
| Bowden, GT | 1 |
| Dalton, WS | 1 |
| Mackel, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| MOSAIC-P: Mindfulness Online for Symptom Alleviation and Improvement in Cancer of the Prostate[NCT03853902] | 30 participants (Actual) | Interventional | 2016-01-26 | Completed | |||
| MITOXANTRONE (N) VS. 5-FLUOROURACIL, EPIRUBICIN AND CYCLOPHOSPHAMIDE AS FIRST-LINE CHEMOTHERAPY FOR PATIENTS WITH METASTATIC BREAST CANCER AND AN UNFAVORABLE PROGNOSIS[NCT00002544] | Phase 3 | 300 participants (Anticipated) | Interventional | 1993-05-31 | Completed | ||
| Randomized Placebo-Controlled Trial of Mitoxantrone/Prednisone and Clodronate Versus Mitoxantrone/Prednisone Alone in Patients With Hormone Refractory Metastatic Prostate Cancer and Pain[NCT00003232] | Phase 3 | 227 participants (Actual) | Interventional | 1997-11-24 | Completed | ||
| Docetaxel and Estramustine Versus Mitoxantrone and Prednisone for Advanced, Hormone Refractory Prostate Cancer[NCT00004001] | Phase 3 | 770 participants (Actual) | Interventional | 1999-10-31 | Completed | ||
| Randomized, Placebo Controlled, Phase II Trial, on the Effect of an Oral Supplement,TK3 (Tryptophan and Thiamine) on the Quality of Life and Chemotherapy Tolerance in Cancer Patients With Advanced Disease.[NCT03341286] | Phase 2 | 140 participants (Anticipated) | Interventional | 2017-11-30 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for mitoxantrone and Bone Cancer
| Article | Year |
|---|---|
Skeletal metastases and impact of anticancer and bone-targeted agents in patients with castration-resistant prostate cancer.
Topics: Androstenes; Anilides; Antineoplastic Agents; Benzamides; Bone Density Conservation Agents; Bone Neo | 2016 |
Quality of life with advanced metastatic prostate cancer.
Topics: Androgen Antagonists; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone Neoplasms; Deno | 2012 |
The changing pattern of management for hormone-refractory, metastatic prostate cancer.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocol | 2006 |
New agents in the therapy of hormone-refractory patients with prostate cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Humans; Male; Mitoxantrone; Prostate | 1995 |
22 trials available for mitoxantrone and Bone Cancer
| Article | Year |
|---|---|
Cabozantinib Versus Mitoxantrone-prednisone in Symptomatic Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 3 Trial with a Primary Pain Endpoint.
Topics: Aged; Analgesics; Anilides; Bone Neoplasms; Cancer Pain; Double-Blind Method; Drug Combinations; Hum | 2019 |
Initial biopsy Gleason score as a predictive marker for survival benefit in patients with castration-resistant prostate cancer treated with docetaxel: data from the TAX327 study.
Topics: Adenocarcinoma; Antineoplastic Agents; Biopsy; Bone Neoplasms; Docetaxel; Humans; Male; Mitoxantrone | 2014 |
What is the real impact of bone pain on survival in patients with metastatic hormone-refractory prostate cancer treated with docetaxel?
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Cohort Studies; Docetaxel; Humans; M | 2009 |
[Toxicity and efficacy of intermittent docetaxel chemotherapy for hormone refractory prostate cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Dise | 2009 |
A phase I/II study of combined chemotherapy with mitoxantrone and uracil/tegafur for advanced hepatocellular carcinoma.
Topics: Adrenal Gland Neoplasms; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carci | 2011 |
Is first-line single-agent mitoxantrone in the treatment of high-risk metastatic breast cancer patients as effective as combination chemotherapy? No difference in survival but higher quality of life were found in a multicenter randomized trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Bone Neoplasms; Breast | 2002 |
Phase I/II study of gemcitabine plus mitoxantrone as salvage chemotherapy in metastatic breast cancer.
Topics: Adult; Aged; Bone Neoplasms; Breast Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug | 2003 |
Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Clodronic Acid; Disease Progre | 2003 |
High-dose chemotherapy and autologous stem cell rescue for metastatic breast cancer: superior survival for tandem compared with single transplants.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carbo | 2005 |
Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Docetaxel; | 2006 |
Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Docetaxel; | 2006 |
Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Docetaxel; | 2006 |
Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Docetaxel; | 2006 |
Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocol | 2007 |
Mitoxantrone plus vinorelbine in pretreated patients with metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brai | 2007 |
High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplant | 1995 |
Folinic acid, 5-fluorouracil bolus and infusion and mitoxantrone with or without cyclophosphamide in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Cyclo | 1993 |
Randomised phase II study of epirubicin-vindesine versus mitoxantrone-vindesine in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Diges | 1995 |
Convergent discriminitive, and predictive validity of the Prostate Cancer Specific Quality of Life Instrument (PROSQOLI) assessment and comparison with analogous scales from the EORTC QLQ-C30 and a trial-specific module. European Organisation for Research
Topics: Analysis of Variance; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Bone Neoplasms; Cross- | 1999 |
Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocol | 1999 |
A phase II study of two cycles of high-dose chemotherapy with autologous stem cell support in patients with metastatic breast cancer who meet eligibility criteria for a single cycle.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carboplatin | 2000 |
Is salvage chemotherapy for metastatic breast cancer always effective and well tolerated? A phase II randomized trial of vinorelbine versus 5-fluorouracil plus leucovorin versus combination of mitoxantrone, 5-fluorouracil plus leucovorin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Femal | 2000 |
Randomized clinical trial comparing mitoxantrone with epirubicin and with doxorubicin, each combined with cyclophosphamide in the first-line treatment of patients with metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Cyclophosphamide; | 1990 |
A clinical trial of mitoxantrone (novantrone) versus doxorubicin (adriamycin) in combination chemotherapy for metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Clini | 1987 |
Phase II trial of mitoxantrone in advanced sarcomas: a Southwest Oncology Group study.
Topics: Adolescent; Adult; Aged; Anthraquinones; Antineoplastic Agents; Bone Neoplasms; Clinical Trials as T | 1985 |
19 other studies available for mitoxantrone and Bone Cancer
| Article | Year |
|---|---|
Docetaxel-rechallenge in castration-resistant prostate cancer: defining clinical factors for successful treatment response and improvement in overall survival.
Topics: Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Disease-Free Surv | 2018 |
Combining oncolytic HSV-1 with immunogenic cell death-inducing drug mitoxantrone breaks cancer immune tolerance and improves therapeutic efficacy.
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; CD8-Positive T-Lymphocytes; Cell Death; Cell Line, T | 2013 |
Expression of noncoding vault RNA in human malignant cells and its importance in mitoxantrone resistance.
Topics: Antineoplastic Agents; Base Sequence; Bone Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; G | 2010 |
Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols | 2012 |
[Therapy of painful bone metastases in patients with prostate carcinoma. The AP 32/02 Study of the AUO].
Topics: Antineoplastic Agents; Bone Neoplasms; Diphosphonates; Humans; Ibandronic Acid; Male; Mitoxantrone; | 2004 |
Radiotherapy is a cost-effective palliative treatment for patients with bone metastasis from prostate cancer.
Topics: Analgesics; Antineoplastic Agents; Bone Neoplasms; Cost-Benefit Analysis; Humans; Male; Markov Chain | 2004 |
The postchemotherapy PSA surge syndrome.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents; Antineo | 2008 |
Treatment of metastatic sarcomas with mitoxantrone.
Topics: Agranulocytosis; Anthraquinones; Antineoplastic Agents; Bone Neoplasms; Drug Evaluation; Female; Hum | 1984 |
[Microinvasive CT-controlled tumor therapy of soft tissue and skeletal metastases].
Topics: Adult; Aged; Aged, 80 and over; Bone Neoplasms; Combined Modality Therapy; Ethanol; Female; Humans; | 1993 |
[Advanced breast cancer with remarkable response to the combination therapy of mitoxantrone (MIT) and medroxyprogesteron acetate (MPA) after failure of anthracycline therapy: a case report].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carcinoma, D | 1994 |
[Combined mitoxantrone therapy for heavily pretreated metastatic breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Doxor | 1993 |
Evaluation of single-agent chemotherapy for treatment of clinically evident osteosarcoma metastases in dogs: 45 cases (1987-1991).
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Chemotherapy, Adjuvant; Cisplatin; Dog Diseases; Dog | 1993 |
Mitoxantrone in the treatment of metastatic transitional cell carcinoma of the prostate. A case report.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 1997 |
Treatment of previously treated metastatic breast cancer by mitoxantrone and 48-hour continuous infusion of high-dose 5-FU and leucovorin (MFL): low palliative benefit and high treatment-related toxicity.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasm | 1997 |
["Radiation recall"].
Topics: Aged; Bone Neoplasms; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Female; H | 1997 |
[Chemotherapy with mitoxantrone for the treatment of recurrent breast cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Drug Administratio | 2000 |
Longitudinal effects of high-dose chemotherapy and autologous stem cell transplantation on quality of life in the treatment of metastatic breast cancer.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Anxiety; Arthralgia; Bone Neoplas | 2001 |
Experience with methotrexate, 5-fluorouracil, and leucovorin (MFL): a first line effective, minimally toxic regimen for metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brai | 2002 |
Pharmacology of mitoxantrone: mode of action and pharmacokinetics.
Topics: Animals; Anthraquinones; Antineoplastic Agents; Bone Marrow; Bone Neoplasms; Chromatography, High Pr | 1985 |